- Report
- March 2024
- 188 Pages
Global
From €3205EUR$3,374USD£2,757GBP
€3562EUR$3,749USD£3,064GBP
- Report
- May 2024
- 372 Pages
Global
From €5178EUR$5,450USD£4,454GBP
- Report
- November 2023
- 146 Pages
Global
From €2374EUR$2,499USD£2,042GBP
- Report
- October 2023
- 150 Pages
Global
From €4608EUR$4,850USD£3,964GBP
- Report
- May 2024
- 546 Pages
Global
From €6645EUR$6,995USD£5,717GBP
- Report
- May 2024
- 541 Pages
Global
From €6645EUR$6,995USD£5,717GBP
- Report
- August 2023
- 1500 Pages
Global
From €8313EUR$8,750USD£7,151GBP
- Report
- October 2023
- 253 Pages
Global
From €4703EUR$4,950USD£4,045GBP
- Report
- May 2024
- 199 Pages
Global
From €3205EUR$3,374USD£2,757GBP
€3562EUR$3,749USD£3,064GBP
- Report
- May 2024
- 158 Pages
Global
From €5178EUR$5,450USD£4,454GBP
- Report
- January 2024
- 200 Pages
Global
From €4750EUR$5,000USD£4,086GBP
- Report
- December 2023
- 200 Pages
Global
From €3800EUR$4,000USD£3,269GBP
- Report
- January 2024
- 182 Pages
Global
From €4655EUR$4,900USD£4,005GBP
- Report
- June 2023
- 115 Pages
Global
From €4275EUR$4,500USD£3,678GBP
- Report
- January 2024
- 200 Pages
Global
From €3943EUR$4,150USD£3,392GBP
- Report
- September 2021
- 144 Pages
China
From €3800EUR$4,000USD£3,269GBP
- Report
- June 2021
- 197 Pages
Latin America
From €3800EUR$4,000USD£3,269GBP
- Report
- July 2020
- 300 Pages
Global
From €5225EUR$5,500USD£4,495GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4750EUR$5,000USD£4,086GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4750EUR$5,000USD£4,086GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more